Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for phrenic nerve stimulators, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS phrenic nerve stimulator coverage policy has been updated, and if your practice bills for this device or the procedures surrounding it, you need to pay attention now — not after your first denial. The policy does not list a specific policy code in CMS's standard NCD or LCD framework for this change. The policy data available does not include specific CPT or HCPCS codes, so this post covers what's known from the policy structure, clinical context, and what your billing team should do while the full code-level detail is confirmed.
| Field | Detail |
|---|---|
| Payer | CMS |
| Policy | Phrenic Nerve Stimulator |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Pulmonology, Neurology, Thoracic Surgery, Neurosurgery, Respiratory Therapy, DME Suppliers |
| Key Action | Audit your phrenic nerve stimulator claims and prior authorization workflows before May 15, 2026 |
CMS Phrenic Nerve Stimulator Coverage Criteria and Medical Necessity Requirements 2026
The phrenic nerve stimulator — also called a diaphragm pacing system — is an implantable device that electrically stimulates the phrenic nerve to drive diaphragm contraction. It's used for patients with respiratory insufficiency who cannot breathe without support, particularly those with high cervical spinal cord injury or central hypoventilation syndromes.
CMS has modified its coverage policy for this device, and the modification is marked as effective May 15, 2026. The payer data provided does not include the specific revised medical necessity criteria text, but the direction of CMS modifications to implantable neurostimulator policies in recent years has consistently moved toward tighter documentation requirements and narrower indications.
What this means practically: if your team has been billing for phrenic nerve stimulator implantation, follow-up programming, or related durable medical equipment under assumptions from an older policy, those assumptions may no longer hold after May 15, 2026.
What CMS Generally Requires for Phrenic Nerve Stimulator Coverage
Even without the revised criteria text in the policy data, the clinical and billing framework around phrenic nerve stimulators is well-established. CMS has historically required all of the following for coverage:
| # | Covered Indication |
|---|---|
| 1 | A diagnosis of chronic respiratory insufficiency due to upper motor neuron disease or high cervical spinal cord injury |
| 2 | Documented ventilator dependence, typically for a minimum defined period |
| 3 | Intact phrenic nerve function confirmed by electrophysiologic testing |
| 4 | Physician attestation that the patient is a surgical candidate |
| 5 | Implantation performed by a qualified surgeon at an appropriate facility |
Medical necessity documentation is not optional here — it's the difference between payment and a claim denial. CMS auditors have flagged phrenic nerve stimulator claims before for insufficient documentation of phrenic nerve viability. If your medical records don't clearly show pre-operative nerve conduction studies, you're exposed.
Prior authorization requirements for this device depend on your Medicare Administrative Contractor jurisdiction. Some MACs have issued local coverage determinations that layer additional requirements on top of any national policy. Check with your MAC directly, and do it before May 15, 2026.
The reimbursement at stake here is significant. Phrenic nerve stimulator systems are high-cost implantable devices. The facility and professional component billing, the device itself, and ongoing programming visits all depend on the foundation of a clean, defensible medical necessity determination.
CMS Phrenic Nerve Stimulator Exclusions and Non-Covered Indications
CMS does not cover phrenic nerve stimulators for every respiratory condition. The non-covered indications are consistent across policy iterations and worth restating clearly for billing teams.
Patients with lower motor neuron disease — including amyotrophic lateral sclerosis (ALS) in most presentations — are generally not candidates for covered phrenic nerve stimulation under CMS. The phrenic nerve itself must be intact for stimulation to work. If the nerve is damaged at the lower motor neuron level, stimulation won't produce diaphragm contraction, and CMS excludes these cases from coverage on that basis.
Patients with chronic obstructive pulmonary disease, neuromuscular disorders without clear phrenic nerve involvement, or respiratory failure from primary pulmonary pathology also fall outside the covered indications. Billing for phrenic nerve stimulator implantation in these populations will generate a claim denial.
ALS is the gray area that generates the most confusion — and the most denials. Some trials have explored phrenic nerve pacing in ALS patients, but CMS has historically classified this as investigational in most ALS presentations. If your practice treats ALS patients and has been exploring this therapy, talk to your compliance officer before submitting any related claims under the modified policy.
Coverage Indications at a Glance
The policy data provided does not include specific indication-level coverage criteria with associated codes. The table below reflects established CMS coverage framework for phrenic nerve stimulators. Verify against the full modified policy text before May 15, 2026.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| High cervical spinal cord injury (C1–C2) with ventilator dependence | Covered (when criteria met) | Not specified in policy data | Requires intact phrenic nerve confirmed by EMG/nerve conduction |
| Central hypoventilation syndrome (congenital or acquired) | Covered (when criteria met) | Not specified in policy data | Documentation of failed or unsuitable conventional ventilation required |
| ALS with respiratory failure | Typically Not Covered / Investigational | Not specified in policy data | CMS has historically excluded most ALS presentations; verify with MAC |
| Lower motor neuron disease with phrenic nerve damage | Not Covered | Not specified in policy data | Nerve must be intact for stimulation to function |
| COPD or primary pulmonary pathology | Not Covered | Not specified in policy data | Outside covered indications |
| Post-operative diaphragm pacing follow-up programming | Covered (when device is covered) | Not specified in policy data | Programming visits require separate documentation of medical necessity |
CMS Phrenic Nerve Stimulator Billing Guidelines and Action Items 2026
The policy data does not include revised billing guidelines text, but the May 15, 2026 effective date is real, and your team should act now. Here's what to do.
| # | Action Item |
|---|---|
| 1 | Pull your phrenic nerve stimulator claims from the last 12 months. Identify every claim related to phrenic nerve stimulator implantation, programming, and related procedures. This is your baseline. You need to know your volume, your payer mix, and where Medicare is in that mix before May 15, 2026. |
| 2 | Get the full modified policy text directly from CMS. The policy data available for this post does not include the revised criteria language. Go to the CMS website or your MAC's website and pull the current policy document. If a local coverage determination from your MAC governs this procedure in your region, pull that too. Do not rely on summaries — read the source document. |
| 3 | Audit your medical necessity documentation templates. Phrenic nerve stimulator billing lives or dies on documentation. Your pre-operative workup notes, phrenic nerve electrophysiology results, and physician attestation statements need to satisfy whatever criteria the modified policy now requires. Update your templates before the effective date. |
| 4 | Confirm prior authorization requirements with your MAC. Prior authorization workflows for implantable neurostimulators vary by MAC jurisdiction. Contact your MAC or check their website for any updated prior auth requirements tied to this policy modification. A prior auth denial is worse than a claim denial — it stops the case before it starts. |
| 5 | Flag your coding team to watch for updated CPT and HCPCS codes. The policy data does not list specific codes. This could mean the code set is unchanged, or it could mean updated codes are forthcoming. Watch for any CMS transmittals or MAC bulletins that tie specific codes to the modified policy. Set up a watch on the CMS transmittal feed now. |
| 6 | Review your DME billing relationships. If your practice works with a durable medical equipment supplier for the external components of the phrenic nerve stimulator system, make sure they're aware of this policy modification. DME billing guidelines for implantable stimulator systems often run parallel to the physician/facility policy, and a mismatch creates downstream claim issues. |
| 7 | Loop in your compliance officer if you have ALS patients in this pathway. The ALS indication is the highest-risk area. If your practice has been billing phrenic nerve stimulator procedures for ALS patients under any interpretation of prior policy, the modified coverage policy may close that window entirely. Don't wait for a denial to find out. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Phrenic Nerve Stimulator Under This Policy
The policy data provided for this change does not list specific CPT, HCPCS, or ICD-10 codes. Do not use this absence as permission to assume your current codes are unaffected.
Phrenic nerve stimulator billing typically involves a combination of implantation CPT codes, programming/management codes, and HCPCS codes for the device itself. ICD-10 diagnosis codes for high cervical spinal cord injury and central hypoventilation syndromes are central to medical necessity documentation.
Until CMS publishes or confirms the specific code set tied to this modified policy, work from the full policy text you pull directly from CMS or your MAC. If you're not sure which codes apply to your specific claim scenarios under the modified policy, talk to a qualified billing consultant or your compliance officer before the May 15, 2026 effective date.
When the code-level data becomes available, PayerPolicy will update this post with the full code tables. This policy is actively tracked at app.payerpolicy.org/p/cms/244-v1. provided.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.